Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01324414 · ClinicalTrials.gov registry record

Impact of Muscle Insulin Resistance on the Pathogenesis of Non Alcoholic Steatohepatitis

A clinical trial of Non Alcoholic Fatty Liver Diseases (NAFLD), sponsored by Mayo Clinic.

Completed
Registry status
90
Enrollment target
1
Study location

NCT01324414: Completed study of Non Alcoholic Fatty Liver Diseases (NAFLD), sponsored by Mayo Clinic.

NCT01324414 is a study of Non Alcoholic Fatty Liver Diseases (NAFLD) that has completed, run by Mayo Clinic. The registered enrollment target is 90 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01324414, a study of Non Alcoholic Fatty Liver Diseases (NAFLD), has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
90 participants
Enrollment target
1
Study location

Study Summary

The incidence of Non alcoholic fatty liver disease (NAFLD) continues to increase, and prevalence estimates for NAFLD range from 17-33%, making it is the most common cause of chronic liver disease in North America. It is associated with increased cardiovascular morbidity as well as progression to cirrhosis is a subset of patients. There is currently no approved treatment for NAFLD. A key barrier to the development of effective therapies is a lack of consensus on the criteria for diagnosis and endpoints for studies evaluating diagnostic markers, prognosis and therapeutic modalities. NAFLD encompasses an entire pathological spectrum of disease, from relatively benign accumulation of lipid (steatosis) to progressive non alcoholic steatohepatitis (NASH) associated with inflammation, fibrosis, and necrosis. It has been estimated that 20-30% of patients with NAFLD will exhibit biochemical and histological changes characteristic of NASH, and 15-20% of those patients will progress to have cirrhosis. NASH remains an important phenotypic state, because this sub-group of patients is deemed at high-risk for developing progressive disease resulting in cirrhosis, liver failure requiring transplantation, or death. Although NAFLD has not to date been included as a component of the metabolic syndrome, there is increasing evidence that NAFLD frequently accompanies the development of insulin resistance and therefore may be an indicator or predictor of future cardiometabolic risk. Moreover, recent findings in skeletal muscle of experimental insulin resistance (lipid infusion) as well as naturally occurring obese and type 2 diabetic, insulin resistant patients show that skeletal muscle inflammation leads to a pattern of extracellular matrix, structural, and remodeling abnormalities that closely resemble the TGFb, connective tissue growth factor (CTGF) mediated fibrotic response that differentiates simple steatotic liver from NASH. This suggests there may be a common underlying mechanis

Study Locations (1)

Arizona

  • Mayo Clinic - Phoenix

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2010-12
Est. Completion 2016-01
Mayo Clinic

2,844 total trials

What the finished NCT01324414 record still lists

NCT01324414 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 90 participants, a relatively small participant target.

The record links to 1 condition, with Non Alcoholic Fatty Liver Diseases (NAFLD) appearing as the primary indexed condition, and to 0 interventions.

NCT01324414 reports a single indexed study location in Arizona.

Frequently Asked Questions

What is clinical trial NCT01324414 about?

NCT01324414 is a clinical study titled "Impact of Muscle Insulin Resistance on the Pathogenesis of Non Alcoholic Steatohepatitis". The incidence of Non alcoholic fatty liver disease (NAFLD) continues to increase, and prevalence estimates for NAFLD range from 17-33%, making it is the most common cause of chronic liver disease in North America. It is associated with increased cardiovascular morbidity as well as progression to cir...

What is the current status of trial NCT01324414?

This trial is currently completed. The enrollment target is 90 participants. The study started on 2010-12. Estimated completion is 2016-01.

What conditions does trial NCT01324414 study?

This clinical trial studies the following conditions: Non Alcoholic Fatty Liver Diseases (NAFLD).

Who is sponsoring clinical trial NCT01324414?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01324414 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02521311 · 90 participants · Phase 2

    Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)

  • NCT02939573 · 90 participants · Phase 2

    A Randomized Multicenter Study for Isolated Skin Vasculitis

  • NCT03128879 · 90 participants · Phase 2

    Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

  • NCT03184038 · 90 participants · NA

    Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01324414, the US trial registry maintained by the National Library of Medicine. NCT01324414 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.